Brief: Aeon Biopharma Inc- Topline Data Expected To Be Announced In 2H 2023
21/12/2022 13:08
Dec 21 (Reuters) - Aeon Biopharma AEON.O :
* AEON BIOPHARMA WHICH IS MERGING WITH PRIVETERRA
ACQUISITION
CORP. SAYS TOPLINE DATA EXPECTED TO BE ANNOUNCED IN 2H 2023
* AEON BIOPHARMA COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF
ABP-450
FOR PREVENTIVE TREATMENT OF EPISODIC MIGRAINE
* AEON BIOPHARMA INC- TOPLINE DATA EXPECTED TO BE ANNOUNCED
IN 2H
2023
Source text for Eikon: ID:
Further company coverage: AEON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition